Médecins Sans Frontières’ Access Campaign says the Special 301 Report threatens countries like India with sanctions at the behest of pharmaceutical corporations and is aimed at blocking more affordable generic versions of drugs NEW DELHI : The US Trade Representative's (USTR) move to keep India on the priority watch list for patenting norms can be used to block access for affordable drugs against covid-19, said health activists.
The USTR late Wednesday released its Special 301 Report, in which it continued to place India on the 'Priority Watch List' for lack of sufficient improvement to its intellectual property framework.